238 related articles for article (PubMed ID: 7710428)
1. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
Marzo A; Balant LP
Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
[TBL] [Abstract][Full Text] [Related]
2. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
3. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
4. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
Meredith PA
Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
[TBL] [Abstract][Full Text] [Related]
5. [Bioequivalence studies of pharmaceutical preparations].
Vetchý D; Frýbortová K; Rabisková M; Danecková H
Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
7. The new European Medicines Agency guideline on the investigation of bioequivalence.
Morais JA; Lobato Mdo R
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of generic aerosol bronchodilators: what are the issues?
Spino M
CMAJ; 1989 Nov; 141(9):883-7. PubMed ID: 2804845
[TBL] [Abstract][Full Text] [Related]
9. The transitivity of bioequivalence testing: potential for drift.
Anderson S; Hauck WW
Int J Clin Pharmacol Ther; 1996 Sep; 34(9):369-74. PubMed ID: 8880284
[TBL] [Abstract][Full Text] [Related]
10. Critical considerations into the new EMA guideline on bioequivalence.
Marzo A; Fontana E
Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
[TBL] [Abstract][Full Text] [Related]
11. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
12. The subject-by-formulation interaction in multivariate bioequivalence.
Cao L; Mathew T
J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence studies: single vs multiple dose.
Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S31-6. PubMed ID: 1601529
[TBL] [Abstract][Full Text] [Related]
14. Current challenges facing the determination of product bioequivalence in veterinary medicine.
Martinez MN; Hunter RP
J Vet Pharmacol Ther; 2010 Oct; 33(5):418-33. PubMed ID: 20840385
[TBL] [Abstract][Full Text] [Related]
15. Reference tables for the intrasubject coefficient of variation in bioequivalence studies.
Steinijans VW; Sauter R; Hauschke D; Diletti E; Schall R; Luus HG; Elze M; Blume H; Hoffmann C; Franke G
Int J Clin Pharmacol Ther; 1995 Aug; 33(8):427-30. PubMed ID: 8556220
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence and narrow therapeutic index drugs.
Benet LZ; Goyan JE
Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
[TBL] [Abstract][Full Text] [Related]
18. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
19. [Bioequivalence and therapeutic exchange of pharmaceutical specialties: application to cyclosporin in renal transplantation].
Pérez Ruixo JJ; Porta B; Jiménez Torres NV
Nefrologia; 2003; 23(1):71-80. PubMed ID: 12708379
[TBL] [Abstract][Full Text] [Related]
20. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
Zapater P; Horga JF
Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]